专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明公开

EP2265718A1 METHODS INVOLVING MS4A12 AND AGENTS TARGETING MS4A12 FOR THERAPY, DIAGNOSIS AND TESTING 审中-公开
标题翻译：与MS4A12和MS4A12-ACTIVE进行治疗，诊断和试验过程
公开(公告)号：EP2265718A1
公开(公告)日：2010-12-29
申请号：EP09731038.7
申请日：2009-03-30
申请人： Ganymed Pharmaceuticals AG , Johannes Gutenberg-Universität Mainz
发明人： SAHIN, Ugur , TÜRECI, Özlem , KOSLOWSKI, Michael
IPC分类号： C12N15/11 , A61K39/00 , G01N33/68 , C07K14/705
CPC分类号： C12N15/1138 , A61K2039/505 , C12N2310/11 , C12N2310/111 , C12N2310/14 , G01N33/5011 , G01N33/57419 , G01N2333/485 , G01N2333/70596
摘要： The invention relates to methods involving MS4A12 and agents targeting MS4A12 which are useful for therapy, diagnosis and testing of disease states, in particular cancer diseases. In particular, the invention relates to agents which reduce or inhibit expression or activity of MS4A12, compositions containing these agents, and methods for reducing, determining, or increasing the responsiveness of a cell towards EGF.

52. 发明公开

EP2203472A2 IDENTIFICATION OF TUMOR-ASSOCIATED MARKERS FOR DIAGNOSIS AND THERAPY 审中-公开
标题翻译：识别肿瘤相关标志物用于诊断和治疗
公开(公告)号：EP2203472A2
公开(公告)日：2010-07-07
申请号：EP08843314.9
申请日：2008-10-22
申请人： Ganymed Pharmaceuticals AG , Johannes Gutenberg-Universität Mainz
发明人： SAHIN, Ugur , TÜRECI, Özlem , KOSLOWSKI, Michael
IPC分类号： C07K14/47
CPC分类号： C12Q1/6886 , C07K14/4748 , C07K16/30 , C12Q2600/118 , C12Q2600/158
摘要： The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

53. 发明公开

EP1861118A2 IDENTIFIZIERUNG VON OBERFLÄCHEN-ASSOZIIERTEN ANTIGENEN FÜR DIE TUMORDIAGNOSE UND -THERAPIE 有权转让
标题翻译： IDENTIFIZIERUNG VONOBERFLÄCHEN-ASSOZIIERTEN ANTIGENENFÜRDIE TUMORDIAGNOSE UNDERTHERAPIE
公开(公告)号：EP1861118A2
公开(公告)日：2007-12-05
申请号：EP06723678.6
申请日：2006-03-23
申请人： Ganymed Pharmaceuticals AG
发明人： SAHIN, Ugur , TÜRECI, Özlem , KOSLOWSKI, Michael , HELFTENBEIN, Gerd , USENER, Dirk , SCHLÜTER, Volker
IPC分类号： A61K39/00 , A61K48/00 , C07K14/47
CPC分类号： G01N33/57492 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G06F19/22
摘要： Pharmaceutical composition (A) comprises an agent (I) that inhibits the expression or activity of tumor-associated antigens (TAg) that are encoded by particular nucleic acids (NA). Pharmaceutical composition (A) comprises an agent (I) that inhibits the expression or activity of tumor-associated antigens (TAg) that are encoded by particular nucleic acids (NA) which are: (a) any of seq. 13, 1, 5, 9, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105,109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211, 215, 219, 223, 227, 231, 235, 239, 243, 247, 251, 255, 259, 263, 267, 269, 271, 273, 275, 277, 279, 309, 313 or their parts or derivatives; (b) a sequence that hybridizes to (a) under stringent conditions; (c) a degenerate variant of (a) or (b); or (d) a complement of (a)-(c). Independent claims are also included for: (1) pharmaceutical composition (A1) containing a tumor-inhibiting agent (II) that is selective for cells that show (abnormal) expression of TAg; (2) pharmaceutical composition (A2) containing an agent (III) that selectively increases the amount of a complex formed between TAg and an HLA (human lymphocyte antigen) molecule; (3) diagnosing diseases characterized by (abnormal) expression of TAg by detecting at least one of NA, TAg, antibodies specific for TAg, cytotoxic or helper T lymphocytes specific for TAg in a patient sample; (4) detecting regression, progression or outbreak of a disease associated with (abnormal) expression of TAg by monitoring patient samples for at least one of NA, TAg, specific antibodies and/or cytolytic/cytokine-secreting T cells specific for a complex between TAg and MHC (major histocompatibility complex) molecules; (5) NA as defined above as new, including fragments and derivatives; (6) recombinant DNA and RNA that includes NA of (5); (7) host cell containing the NA of (5) or recombinant DNA of (6); (8) protein or polypeptide (Z) encoded by NA, having any of seq. n+1 where n = any seq. number for NA listed above, and their immunogenic fragments; (9) agents (X) that bind specifically to (Z); (10) antibodies (Ab) that bind selectively to a complex formed from (Z) and an MHC molecule, but not to either of the complex components alone; (11) conjugate between (X) or Ab and a therapeutic or diagnostic agent; (12) kit for detecting (abnormal) expression of TAg; (13) recombinant DNA comprising a promoter region and any of the specified NA sequences; and (14) antibodies that bind to an extracellular region of proteins seq. n+1. - ACTIVITY : Cytostatic. No biological data given. - MECHANISM OF ACTION : Inhibiting expression and/or activity of specific antigens.
摘要翻译：药物组合物（A）包含抑制由特定核酸（NA）编码的肿瘤相关抗原（TAg）的表达或活性的试剂（I）。药物组合物（A）包含抑制由特定核酸（NA）编码的肿瘤相关抗原（TAg）的表达或活性的试剂（I），其特征在于：（a） 13，1，5，9，17，21，25，29，33，37，41，45，49，53，57，61，65，69，73，77，81，85，89，93， 101,105,109,113,117,121,125,129,133,137,141,145,149,153,157,161,165,169,173,175,179,183,187,191,195,1999， 203,207,211,215,219,223,227,231,235,239,243,247,251,255,259,263,267,269,227,231,235,239,237,237,251,255,259,237,251,255,259,237,251,255,259,237,251,255,259,237,257,237,237,237,237,237,237,237,237,237,237,237,237,237,237,237,237,237 其部分或衍生物; （b）在严格条件下与（a）杂交的序列; （c）（a）或（b）的简并变体; 或（d）（a） - （c）的补语。还包括独立权利要求：（1）含有显示（异常）TAg表达的细胞的选择性的肿瘤抑制剂（II）的药物组合物（A1）（2）含有选择性增加TAg与HLA（人淋巴细胞抗原）分子之间形成的复合物的量的试剂（III）的药物组合物（A2）（3）通过检测患者样品中TAg特异性的TAg，特异于TAg的细胞毒性或辅助性T淋巴细胞中的至少一种来诊断特征为（异常）TAg表达的疾病，（4）通过监测针对NA，TAg，特异性抗体和/或细胞因子/细胞因子分泌型T细胞中的至少一种对于复合物之间的复合物的特异性的至少一种来检测与TAG的（异常）表达相关的疾病的回归，进展或爆发 TAg和MHC（主要组织相容性复合物）分子; （5）以新定义的NA，包括片段和衍生物; （6）包含（5）的NA的重组DNA和RNA; （7）含有（5）的NA或（6）的重组DNA的宿主细胞; （8）由NA编码的蛋白质或多肽（Z），具有以下任何一个。 n + 1其中n =任何seq。上述NA的数量及其免疫原性片段; （9）特异性结合（Z）的试剂（X）; （10）抗体（Ab），其选择性结合由（Z）和MHC分子形成的复合物，但不与任何一种复合成分单独结合; （11）（X）或Ab之间的缀合物和治疗剂或诊断剂; （12）TAg检测（异常）表达试剂盒; （13）包含启动子区和任何指定的NA序列的重组DNA; 和（14）结合蛋白质细胞外区域的抗体。的n + 1。活动：细胞抑制。没有给出生物数据。作用机理：抑制特异性抗原的表达和/或活性。

54. 发明公开

EP1664103A2 DIFFERENTIELL IN TUMOREN EXPRIMIERTE GENPRODUKTE UND DEREN VERWENDUNG 审中-公开
标题翻译：差异表达基因肿瘤产品和它们的用途
公开(公告)号：EP1664103A2
公开(公告)日：2006-06-07
申请号：EP04765088.2
申请日：2004-09-10
申请人： Ganymed Pharmaceuticals AG
发明人： TÜRECI, Özlem , SAHIN, Ugur , KOSLOWSKI, Michael
IPC分类号： C07K14/47 , C07K16/30 , C12Q1/68
CPC分类号： C07K14/4748 , C07K16/30 , C07K2317/34 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154
摘要： The invention relates to the identification of genetic products expressed in association with tumours and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumours, proteins, polypeptides and peptides which are expressed in association with tumours and to the coding nucleic acids for said proteins, polypeptides and peptides.

55. 发明申请

WO2009062481A1 DREHMOMENTMESSEINRICHTUNG, DREHMOMENTMESSFLANSCH UND DREHMOMENTMESSVERFAHREN 审中-公开
标题翻译：扭矩测量装置，扭矩法兰扭矩测量方法
公开(公告)号：WO2009062481A1
公开(公告)日：2009-05-22
申请号：PCT/DE2008/001856
申请日：2008-11-13
申请人： GIF GESELLSCHAFT FÜR INDUSTRIEFORSCHUNG MBH , MEUTER, Herbert , KOSLOWSKI, Michael
发明人： MEUTER, Herbert , KOSLOWSKI, Michael
IPC分类号： G01L25/00 , G01L3/10
CPC分类号： G01L25/003 , G01L3/108
摘要： Um bei einer Drehmomentmesseinrichtung, einem Drehmomentmessflansch sowie einem Drehmomentmessverfahren die Gefahr von Artefakten zu minimieren, wird vorgeschlagen, dass die Auswertung mit Mittel zur Speicherung einer zu einem Freilaufmoment proportionalen Größe und Mittel zur Kompensation eines Messwertes mit der gespeicherten Größe aufweist.
摘要翻译：在一个扭矩测量装置最小化伪影的风险，扭矩和扭矩测量方法中，因此建议的装置，用于存储正比于续流转矩的值的评估和用于补偿的测量值与所存储的大小了。

56. 发明申请

WO2007143986A1 DREHMOMENTMESSFLANSCH 审中-公开
标题翻译：扭矩法兰
公开(公告)号：WO2007143986A1
公开(公告)日：2007-12-21
申请号：PCT/DE2007/001073
申请日：2007-06-14
申请人： GIF GESELLSCHAFT FÜR INDUSTRIEFORSCHUNG MBH , MEUTER, Herbert , KOSLOWSKI, Michael , LANFERMANN, Ralf
发明人： MEUTER, Herbert , KOSLOWSKI, Michael , LANFERMANN, Ralf
IPC分类号： G01L3/14
CPC分类号： G01L3/1457
摘要： Es wird ein Drehmomentmessflansch beziehungsweise allgemein ein Drehmomentmessaufnehmer vorgeschlagen, welcher unterschiedlich ausgebildete Messausnehmungen beziehungsweise unterschiedlich ausgebildete Messmembranen an einem im wesentlichen zylinderförmigen Messbereich aufweist. Auf diese Weise lassen sich leicht verschiedenen Messbereiche erreichen.
摘要翻译：提出了一种扭矩或通常一个Drehmomentmessaufnehmer，包括测量凹部，其不同地设计或不同构造的一个基本圆柱形的测量范围测量膜片。通过这种方式，不同的测量范围是很容易达到。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式